Regulatory press release09.11.2023, 22.15RLS Global AB: RLS Global initiates strategic review process aiming to commercialize ChloraSolv
Regulatory press release09.11.2023, 22.00RLS Global AB: RLS Global and Convatec have agreed to terminate collaboration agreement
Press release06.09.2023, 09.00RLS Global AB: First patient included in new clinical investigation on pressure ulcers
Press release01.09.2023, 13.00RLS Global AB: ChloraSolv recommended for UK CA certification required for UK market after Brexit
Regulatory press release25.08.2023, 09.00RLS Global AB: RLS GLOBAL AB (publ) PUBLISHES INTERIM REPORT FOR THE PERIOD APRIL-JUNE 2023
Regulatory press release24.08.2023, 18.30RLS Global AB: RLS GLOBAL AB (PUBL) RAISES A SHORT-TERM LOAN OF MSEK 5.0
Regulatory press release22.08.2023, 15.00RLS Global AB: RLS Global appoints Torbjörn Sannerstedt as new Chief Financial Officer
Press release01.06.2023, 12.55Redeye: RLS Global Q1 2023: Delay in Europe but progress in the Middle East
Press release20.03.2023, 11.00RLS Global AB: ChloraSolv shows notably greater antibiofilm activity in vitro compared to other debridement products in published article
Press release01.03.2023, 14.48Redeye: RLS Global Q4 2022 - No surprises – but expectations of an eventful 2023
Regulatory press release24.01.2023, 21.40Lars Johansson nominated as new Chairman of the Board of RLS Global AB
Press release09.12.2022, 09.00RLS Global AB: RLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases
Regulatory press release14.11.2022, 22.45RLS Global AB: RLS Global: Outcome in RLS Global's rights issue
Press release10.11.2022, 11.00Presentation by Björn Larsson, CEO, RLS Global AB, about the company's operations and the currently ongoing rights issue
Press release04.11.2022, 14.30RLS Global AB: RLS Global's CEO Björn Larsson interviewed by Erik Penser Bank about the ongoing rights issue